(Reuters) -Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for ...

Keytruda has been approved since 2016 as a second-line option after chemotherapy for patients with more advanced HNSCC that ...

China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price. But this disruptive trend ...

Merck (NYSE:MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting ...

GenBioPro, the largest manufacturer of abortion pills in the U.S., is wading into a federal court case over abortion access ...

Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...

Keytruda demonstrated a statistically significant and clinically meaningful improvement in event-free survival and major ...

The FDA accepted for priority review a supplemental Biologics License Application for Keytruda for resectable locally ...

Merck (MRK) announced the FDA has accepted for priority review a new supplemental Biologics License Application seeking approval for keytruda – ...

Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its blockbuster cancer drug Keytruda in certain patients with head and neck cancer.

The World Health Organization raises alarms over increased West Bank violence affecting healthcare. In Congo, over 50 die due ...